The Latest Cardiac and Vascular News
DANVERS, Mass.–(BUSINESS WIRE)–The benefits of a more complete revascularization with Impella heart pumps in high-risk percutaneous coronary intervention (PCI) patients and the value of Impella protocol-based treatment for survival and native heart recovery in cardiogenic shock patients will be highlighted at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation. […]
NILEMDO® (bempedoic acid) is a new, first-in-class, oral, once-daily treatment which lowers cholesterol and can be combined with other treatments to help lower cholesterol even further1 Bempedoic acid acts on the well-known cholesterol synthesis pathway, upstream of the statin target in the liver, which allows additional LDL-C lowering when added to […]
BOSTON–(BUSINESS WIRE)–Elucid Bioimaging Inc. (“Elucid Bio”) today announced that vascuCAP, Elucid Bio’s AI-enabled software for evaluating atherosclerotic plaque stability from CTA, has been added to the IBM Imaging AI Marketplace, an IBM Watson Health® solution. The IBM Imaging AI Marketplace provides streamlined access to meaningful AI technologies designed to support leaders […]
Trial Met Primary Composite Endpoint of Reduction in Cardiovascular Death or Heart Failure Events Trial Did Not Meet Secondary Endpoint of Reduction in Cardiovascular Death Results Will Be Presented in Late Breaking Clinical Trial Session at AHA Scientific Sessions 2020 THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif. and SURESNES, France, Oct. 8, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN), Cytokinetics, […]
EDEN PRAIRIE, Minn., Oct. 07, 2020 (GLOBE NEWSWIRE) — CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, today announced data from a retrospective study and a case study supporting the benefit of Aquadex™ therapy in the treatment of heart […]
– NEXLETOL® exhibited a 22% mean reduction in LDL-C levels in patients with Heterozygous Familial Hypercholesterolemia at week-12 – ANN ARBOR, Mich., Oct. 07, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced results of pooled data from two of the company’s Phase 3 trials were presented at the virtual […]
Cardiovascular disease remains a leading cause of mortality in both Canada and globally; the lack of reversal agents for patients taking antiplatelet therapies who require urgent surgery or experience a major bleeding event remains a critical unmet need Bentracimab (PB2452) has demonstrated immediate and sustained reversal of the antiplatelet effects […]
NEW YORK, Oct. 06, 2020 (GLOBE NEWSWIRE) — Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces new data presented during the Heart Failure Society of America’s Annual Scientific Meeting focused on the use of Daxor’s BVA-100® blood […]
‘Control Cholesterol’ to Support the NHS in Delivering on Long-Term Plan Ambitions and Improve Health Outcomes for Patients in the North West Coast of England Quality Management Approach Aims to Help Predict and Prevent Heart Attacks and Strokes For More Than 300,000 People With Dangerously High Cholesterol Levels CAMBRIDGE, England–(BUSINESS […]
WINNIPEG, AB, Oct. 5, 2020 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, announces that through its wholly-owned subsidiary, Medicure International Inc., it has entered into a License, Manufacture and Supply Agreement (the “Agreement”) with Reliance Life Sciences Private Limited (“RLS”) for a cardiovascular biosimilar (the […]
